Affordable Access

deepdyve-link deepdyve-link
Publisher Website

PPAR-gamma agonists and their role in type 2 diabetes mellitus management.

Authors
  • Bermúdez, Valmore
  • Finol, Freddy
  • Parra, Nailyn
  • Parra, Maria
  • Pérez, Adriana
  • Peñaranda, Lianny
  • Vílchez, Daviel
  • Rojas, Joselyn
  • Arráiz, Nailet
  • Velasco, Manuel
Type
Published Article
Journal
American journal of therapeutics
Publication Date
Jan 01, 2010
Volume
17
Issue
3
Pages
274–283
Identifiers
DOI: 10.1097/MJT.0b013e3181c08081
PMID: 20216208
Source
Medline
License
Unknown

Abstract

Type 2 diabetes mellitus and obesity are the most frequent endocrine-metabolic diseases in the world and their pathogenic basis are characterized by insulin resistance and insulin secretion defects that can be demonstrated through several alterations in carbohydrates, lipids, and protein metabolism. The peroxisome proliferator-activated receptors have been identified as key regulators of glucose and lipid metabolism, because they act as transcription factors that stimulate protein synthesis in a wide variety of processes (energetic metabolism, proliferation, and cellular differentiation), of which have been identified 3 types (alpha, beta/delta, gamma). The thiazolidenediones are compounds that act as agonists of the peroxisome proliferator-activated receptor-gamma increasing the tissues sensibility (muscle, adiposity tissue, and liver) to the insulin action; that is why they are used nowadays in treatment of type 2 diabetes mellitus. These drugs produce several of adverse effects, such as weight increased, edema, anemia, pulmonary edema, and congestive cardiac failure. Even their use have been related for some studies to an increased in the myocardium infarct risk; this correlation has not been a strong determinant to remove them from the market.

Report this publication

Statistics

Seen <100 times